eltrombopag olamine · Novartis · NDA 207027
Promacta Kit
Earliest generic entry, as listed · earliest of 2 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 207027 · 001 · RLD | for suspension, oral | EQ 25MG ACID/PACKET | open |
| 207027 · 002 · RLD | for suspension, oral | EQ 12.5MG ACID/PACKET | open |
Expired or delisted (5)
- US 7547719 · — · 13 Jan 2026
- US 7547719 · substance, product, use U-2452 · 13 Jul 2025
- US 7547719 · substance, product, use U-1736 · 13 Jul 2025
- US 7547719 · substance, product, use U-1575 · 13 Jul 2025
- US 7547719 · substance, product, use U-1306 · 13 Jul 2025